Cartesian Therapeutics Inc. (RNAC) - Net Assets
Based on the latest financial reports, Cartesian Therapeutics Inc. (RNAC) has net assets worth $-148.12 Million USD as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($288.39 Million) and total liabilities ($436.51 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Cartesian Therapeutics Inc. (RNAC) tangible net worth to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-148.12 Million |
| % of Total Assets | -51.36% |
| Annual Growth Rate | N/A |
| 5-Year Change | -660.54% |
| 10-Year Change | -329.71% |
| Growth Volatility | 297.3 |
Cartesian Therapeutics Inc. - Net Assets Trend (2014–2025)
This chart illustrates how Cartesian Therapeutics Inc.'s net assets have evolved over time, based on quarterly financial data. See how many days can Cartesian Therapeutics Inc. fund operations to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Cartesian Therapeutics Inc. (2014–2025)
The table below shows the annual net assets of Cartesian Therapeutics Inc. from 2014 to 2025. For live valuation and market cap data, see RNAC stock market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $-126.24 Million | -1755.92% |
| 2024-12-31 | $-6.80 Million | +98.45% |
| 2023-12-31 | $-440.18 Million | -569.14% |
| 2022-12-31 | $93.83 Million | +316.62% |
| 2021-12-31 | $22.52 Million | +225.07% |
| 2020-12-31 | $-18.01 Million | -314.43% |
| 2019-12-31 | $8.40 Million | +254.98% |
| 2018-12-31 | $-5.42 Million | -110.46% |
| 2017-12-31 | $51.81 Million | -5.72% |
| 2016-12-31 | $54.96 Million | +147.18% |
| 2015-12-31 | $-116.49 Million | -32.75% |
| 2014-12-31 | $-87.75 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Cartesian Therapeutics Inc.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 73849300000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $3.00K | % |
| Other Comprehensive Income | $-4.58 Million | % |
| Other Components | $700.71 Million | % |
| Total Equity | $-126.24 Million | 100.00% |
Cartesian Therapeutics Inc. Competitors by Market Cap
The table below lists competitors of Cartesian Therapeutics Inc. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
New World Resources Ltd
AU:NWC
|
$172.25 Million |
|
LIWANLI Innovation Co Ltd
TW:3054
|
$172.28 Million |
|
Cambridge Acquisition Corp. Class A Ordinary Shares
NASDAQ:CAQ
|
$172.33 Million |
|
Robot Consulting Co., Ltd. ADS
NASDAQ:LAWR
|
$172.35 Million |
|
Garuda Construction & Engineering
NSE:GARUDA
|
$172.17 Million |
|
Alector Inc
NASDAQ:ALEC
|
$172.17 Million |
|
Hyosung Chemical Corp
KO:298000
|
$172.11 Million |
|
Group Eleven Resources Corp
V:ZNG
|
$172.11 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Cartesian Therapeutics Inc.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from -6,802,000 to -126,240,000, a change of -119,438,000.
- Net loss of 130,302,000 reduced equity.
- Other comprehensive income increased equity by 45,000.
- Other factors increased equity by 10,819,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-130.30 Million | -103.22% |
| Other Comprehensive Income | $45.00K | +0.04% |
| Other Changes | $10.82 Million | +8.57% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Cartesian Therapeutics Inc.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2014-12-31 | $-245.50 | $9.88 | x |
| 2015-12-31 | $-9.05 | $9.88 | x |
| 2016-12-31 | $188.53 | $9.88 | x |
| 2017-12-31 | $91.32 | $9.88 | x |
| 2018-12-31 | $-8.71 | $9.88 | x |
| 2019-12-31 | $6.64 | $9.88 | x |
| 2020-12-31 | $-6.41 | $9.88 | x |
| 2021-12-31 | $7.09 | $9.88 | x |
| 2022-12-31 | $23.16 | $9.88 | x |
| 2023-12-31 | $-85.14 | $9.88 | x |
| 2024-12-31 | $-0.29 | $9.88 | x |
| 2025-12-31 | $-4.86 | $9.88 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Cartesian Therapeutics Inc. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -4658.63%
- • Asset Turnover: 0.01x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-77.29%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2014 | 0.00% | -423.68% | 0.14x | 0.00x | $-4.10 Million |
| 2015 | 0.00% | -418.80% | 0.14x | 0.00x | $-13.52 Million |
| 2016 | -65.89% | -447.98% | 0.09x | 1.62x | $-41.71 Million |
| 2017 | -126.07% | -31556.04% | 0.00x | 1.95x | $-70.50 Million |
| 2018 | 0.00% | -7235.44% | 0.02x | 0.00x | $-64.79 Million |
| 2019 | -659.16% | -828.97% | 0.07x | 11.86x | $-56.19 Million |
| 2020 | 0.00% | -414.99% | 0.10x | 0.00x | $-67.08 Million |
| 2021 | -114.06% | -30.19% | 0.53x | 7.10x | $-27.94 Million |
| 2022 | 37.71% | 31.94% | 0.67x | 1.77x | $26.00 Million |
| 2023 | 0.00% | -844.91% | 0.09x | 0.00x | $-175.69 Million |
| 2024 | 0.00% | -198.97% | 0.09x | 0.00x | $-76.74 Million |
| 2025 | 0.00% | -4658.63% | 0.01x | 0.00x | $-117.68 Million |
Industry Comparison
This section compares Cartesian Therapeutics Inc.'s net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $155,285,360
- Average return on equity (ROE) among peers: -101.11%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Cartesian Therapeutics Inc. (RNAC) | $-148.12 Million | 0.00% | N/A | $172.18 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-34.80 Million | 0.00% | 0.00x | $83.17 Million |
| Abcellera Biologics Inc (ABCL) | $830.51 Million | 14.32% | 0.21x | $1.61 Billion |
| Abeona Therapeutics Inc (ABEO) | $-26.99 Million | 0.00% | 0.00x | $321.39 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $266.97 Million | -19.62% | 0.16x | $155.29 Million |
| Abpro Holdings, Inc. (ABP) | $3.07 Million | -479.81% | 1.57x | $2.00 Million |
| Absci Corp (ABSI) | $179.13 Million | -57.56% | 0.19x | $1.01 Billion |
| Arbutus Biopharma Corp (ABUS) | $182.50 Million | -46.25% | 0.30x | $831.63 Million |
| ABVC Biopharma Inc (ABVC) | $4.59 Million | -357.76% | 1.38x | $35.10 Million |
| Abivax SA American Depositary Shares (ABVX) | $33.94 Million | -14.97% | 0.12x | $7.98 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $113.93 Million | -49.49% | 0.18x | $3.66 Billion |
About Cartesian Therapeutics Inc.
Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides mRNA cell therapies for the treatment of autoimmune diseases. The company's lead product candidate is Descartes-08, an autologous mRNA chimeric antigen receptor T-cell cell therapy (CAR-T) directed against the B cell maturation antigen (BCMA), which is in Phase 2b clinical trials for the treatment of autoimmune disease… Read more